Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease

Abstract

In our cohort of patients with SCD we observed a significant decrease in liver iron burden with high dose IV DFO. Our patients tolerated the therapy well without any major toxicity. This regimen is safe and may be an option for poorly compliant patients with significant iron overload.